CD19 and diffuse large B-cell lymphoma: A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific CAR in Subjects With r/r DLBCL